PRINCETON, NEW JERSEY, March 23, 2026
Bristol Myers Squibb has unveiled new clinical and real-world data for Camzyos (mavacamten) at the American College of Cardiology (ACC) 2026 Annual Scientific Session & Expo, reinforcing its leadership in the treatment of obstructive hypertrophic cardiomyopathy (oHCM). The data includes positive Phase 3 results from the SCOUT-HCM trial and multiple real-world studies demonstrating consistent efficacy, safety, and long-term benefits, highlighting the therapy’s potential to expand into adolescent patient populations and further transform cardiovascular care.
Phase 3 SCOUT-HCM Trial Demonstrates Clinical Efficacy
The SCOUT-HCM Phase 3 clinical trial, a randomized, double-blind, placebo-controlled international study, evaluated the efficacy and safety of Camzyos in adolescents with symptomatic oHCM. The study successfully met its primary endpoint, along with several secondary endpoints, confirming the drug’s clinical benefit in improving cardiac function and patient outcomes.
This marks a significant advancement, as current treatment options for adolescents are largely limited to symptom management rather than disease modification. Camzyos, a cardiac myosin inhibitor, directly targets the underlying mechanism of oHCM—hypercontractility of the heart muscle—thereby reducing left ventricular outflow tract (LVOT) obstruction and improving overall cardiac performance.
The trial results underscore the potential of Camzyos to become the first disease-modifying therapy for adolescents with oHCM, expanding its therapeutic scope beyond adult populations and addressing a critical unmet medical need in cardiology.
Advertisement
Real-World Evidence Confirms Long-Term Safety and Effectiveness
In addition to clinical trial data, real-world evidence from multiple studies, including DISCOVER-HCM, MARVEL-HCM, and COMPASS-HCM, demonstrated the consistent and sustained effectiveness of Camzyos across diverse patient populations. These studies provided valuable insights into the therapy’s performance in routine clinical practice, reinforcing findings observed in controlled clinical trials.
Key outcomes included improvements in patient-reported quality of life, functional capacity, and symptom relief, with some patients experiencing meaningful benefits as early as two weeks after treatment initiation. The data also confirmed a favorable safety profile, with no new safety concerns identified, further supporting the therapy’s long-term use.
Importantly, these findings highlight the growing role of real-world data in complementing clinical trial evidence, providing a more comprehensive understanding of a drug’s impact across broader patient populations. This aligns with regulatory and clinical trends emphasizing evidence-based decision-making and post-market surveillance.
Expanding Therapeutic Impact in Cardiovascular Disease
Camzyos (mavacamten) is currently approved in multiple regions for the treatment of adult patients with symptomatic oHCM, and its expanding evidence base continues to strengthen its position as a paradigm-shifting therapy in cardiovascular medicine. The drug has been prescribed to over 22,000 patients in the United States, reflecting strong adoption and clinical confidence.
By targeting the root cause of oHCM, Camzyos represents a shift toward precision medicine in cardiology, moving beyond symptom control to address underlying disease mechanisms. The therapy’s ability to improve cardiac structure, reduce energy consumption, and enhance patient activity levels underscores its transformative potential.
Bristol Myers Squibb’s ongoing research efforts demonstrate a commitment to advancing innovative cardiovascular therapies, leveraging decades of expertise to address one of the leading causes of global mortality. The continued generation of clinical and real-world evidence will be critical in supporting future regulatory approvals and expanded indications, particularly in younger patient populations.
As the field of cardiology evolves, therapies like Camzyos are expected to play a central role in improving patient outcomes and redefining standards of care, offering new hope for individuals living with complex heart conditions.
Source: Bristol Myers Squibb press release
